ライフサイエンスコーパス: conserving surgery

1 nodes and had completed mastectomy or breast-conserving surgery.

2 changing from radical nephrectomy to nephron-conserving surgery.

3 andard whole-breast irradiation after breast-conserving surgery.

4 ng of TAM and radiotherapy (RT) after breast-conserving surgery.

5 .37) were the strongest predictors of breast-conserving surgery.

6 stics were associated with the use of breast-conserving surgery.

7 esponded and 48% underwent successful breast-conserving surgery.

8 was given to 86% of patients who had breast-conserving surgery.

9 treated with radiotherapy (RT) after breast-conserving surgery.

10 e as likely as other women to undergo breast-conserving surgery.

11 ss likely than other women to undergo breast-conserving surgery.

12 ransient effect on the rate of use of breast-conserving surgery.

13 All had had breast-conserving surgery.

14 influences local recurrence following breast-conserving surgery.

15 e invasive breast cancer treated with breast-conserving surgery.

16 le to downstage tumors and facilitate breast-conserving surgery.

17 <=5 cm) who were scheduled to undergo breast-conserving surgery.

18 mor characteristics; and frequency of breast-conserving surgery.

19 cost of mandatory radiation following breast-conserving surgery.

20 in stage II BC patients treated with breast conserving surgery.

21 fit from neoadjuvant therapy enabling breast-conserving surgery.

22 ssment of tumor margin involvement in breast-conserving surgery.

23 ith a tumor bed boost (WBI arm) after breast-conserving surgery.

24 traoperative margin assessment during breast-conserving surgery.

25 nical application of gGlu-HMRG during breast-conserving surgery.

26 ajority of patients (76.1%) underwent breast-conserving surgery.

27 breast tissue is an important step in breast-conserving surgery.

28 tion of residual cancer tissue during breast-conserving surgery.

29 l carcinoma in situ (DCIS) undergoing breast-conserving surgery.

30 bmitted for surgery, and 10 underwent breast-conserving surgery.

31 r intraoperative margin assessment in breast-conserving surgeries.

32 tential intraoperative use in guiding breast-conserving surgeries.

33 They underwent breast-conserving surgery (1 cm margin) with axillary node samp

34 orbidity for mastectomies (4.0%) than breast conserving surgery (1.6%, P < 0.001).

35 erienced no recurrence, 963 underwent breast-conserving surgery, 263 mastectomy without reconstructio

36 vasive breast cancer, 59.6% underwent breast-conserving surgery, 33.4% underwent unilateral mastectom

37 After breast-conserving surgery, 90% of local recurrences occur withi

38 For those who have undergone breast-conserving surgery, a post-treatment mammogram should be

39 For women who have undergone breast-conserving surgery, a post-treatment mammogram should be

40 After breast-conserving surgery, a total dose of 50.4 Gy was delivere

41 omissions of radiation therapy after breast-conserving surgery, adjuvant chemotherapy after resectio

42 Breast-conserving surgery, adjuvant systemic therapy, and radio

43 00-12.50 Gy/4-5 fractions]) following breast-conserving surgery administered in community-based and a

44 pport the treatment of MO tumors with breast conserving surgery after a detailed clinical evaluation.

45 mpact of tumor biology on the rate of breast-conserving surgery after neoadjuvant chemotherapy has no

46 on, we determined whether the rate of breast-conserving surgery after the legislation was different f

47 tage I-IIA breast cancer treated with breast-conserving surgery, age >= 49 years, were randomly assig

48 0% risk of any local recurrence after breast-conserving surgery alone.

49 rall survival advantage compared with breast-conserving surgery alone.

50 xamined the trend over time in use of breast-conserving surgery among patients in four sites (Connect

51 in both states and the correlates of breast-conserving surgery among women eligible for the procedur

52 to 1.73), but less likely to undergo breast-conserving surgery among women undergoing definitive sur

53 eceived radiation (6474 [96.1%] after breast-conserving surgery and 344 [13.0%] after mastectomy).

54 ative whole-breast radiotherapy after breast-conserving surgery and adjuvant endocrine treatment resu

55 e breast cancer who were treated with breast-conserving surgery and adjuvant systemic therapy to unde

56 ults of studies of radiotherapy after breast-conserving surgery and after mastectomy, and an interpre

57 paclitaxel chemotherapy, followed by breast-conserving surgery and axillary lymph node dissection, w

58 These results support the use of breast-conserving surgery and definitive breast irradiation for

59 treatment of DCIS of the breast using breast-conserving surgery and definitive breast irradiation.

60 breast cancer that were treated with breast-conserving surgery and endocrine therapy alone, the inci

61 like breast cancer, who had undergone breast-conserving surgery and had an Eastern Cooperative Oncolo

62 years (mean, 55.9 years) treated with breast-conserving surgery and irradiation (n = 183) underwent a

63 men have with various providers about breast-conserving surgery and mastectomy.

64 edge gaps in the field of oncoplastic breast-conserving surgery and nipple-sparing or skin-sparing ma

65 9 through 2011, to determine rates of breast-conserving surgery and pCR after chemotherapy by approxi

66 ast cancers have the highest rates of breast-conserving surgery and pCR after neoadjuvant chemotherap

67 or younger at diagnosis treated with breast-conserving surgery and radiation therapy (> or = 60 Gy)

68 d with LR among patients treated with breast-conserving surgery and radiation therapy.

69 cancer patients who were treated with breast-conserving surgery and radiation were analyzed.

70 We compared the outcome of breast-conserving surgery and radiotherapy in BRCA1/2 mutation

71 the proportion of patients receiving breast-conserving surgery and radiotherapy with a simultaneous

72 was 0.85% among patients who received breast-conserving surgery and radiotherapy with RNI; 0.55% afte

73 ly with SPIO and guidewire for breast cancer conserving surgery and resulted in more successful local

74 For patients treated with breast-conserving surgery and RT, the 5-year cumulative inciden

75 All 5210 patients underwent breast-conserving surgery and SLN dissection.

76 ed with vs without the RT boost after breast-conserving surgery and WBRT.

77 ot both, were permitted), who had had breast-conserving surgery and were receiving adjuvant endocrine

78 an half (56%) of the women who had fertility-conserving surgery and who have been in remission at lea

79 658 women who had undergone breast-conserving surgery and who were receiving adjuvant endoc

80 sk ductal carcinoma in situ following breast-conserving surgery and whole breast radiotherapy.

81 carcinoma in situ (DCIS) treated with breast-conserving surgery and whole-breast irradiation (WBRT).

82 ymph node metastases and will receive breast-conserving surgery and whole-breast RT with or without R

83 alyses, mastectomy with radiation (vs breast conserving surgery) and Asian, Black, or American Indian

84 the survey (40.0%; 356 had undergone breast-conserving surgery, and 291 had undergone mastectomy and

85 d, 20% do not receive radiation after breast-conserving surgery, and 30% to 70% of women with lymph n

86 the likelihood that women will choose breast-conserving surgery, and enhances patient knowledge of tr

87 re DCIS (no microinvasion), underwent breast-conserving surgery, and received WBRT with or without th

88 th older age, total mastectomy versus breast-conserving surgery, and reconstructive surgery.

89 f persons undergoing cholecystectomy, breast-conserving surgery, anterior cruciate ligament reconstru

90 gh positive margin rates in oncologic breast-conserving surgery are a pressing clinical problem.

91 mal mortality, recurrence rates after breast-conserving surgery are significant, and half are invasiv

92 Margins of wide local excisions in breast conserving surgery are tested through histology, which c

93 r (cT1-2, N0-1) who were eligible for breast-conserving surgery as per clinicoradiological assessment

94 Breast-conserving surgery at primary diagnosis, locoregional re

95 e (n = 124), 44% of patients received breast-conserving surgery (BCS) after anastrozole compared with

96 Compared with breast-conserving surgery (BCS) alone, there was a decreased li

97 titutions on the use of mastectomy or breast conserving surgery (BCS) among elderly women with breast

98 tients with invasive cancer receiving breast-conserving surgery (BCS) and among patients undergoing m

99 h stage I breast cancers treated with breast-conserving surgery (BCS) and endocrine therapy (ET) with

100 adical mastectomy (MRM) compared with breast-conserving surgery (BCS) and radiation therapy (RT).

101 99, demonstrated that tamoxifen after breast-conserving surgery (BCS) and radiotherapy for ductal car

102 Breast-conserving surgery (BCS) and radiotherapy reduce breast

103 breast cancer patients, treated with breast-conserving surgery (BCS) and whole-breast irradiation (W

104 Inadequate margins in breast-conserving surgery (BCS) are associated with an increase

105 Positive margins following breast-conserving surgery (BCS) are often identified on standar

106 f Health Consensus Statement in 1990, breast-conserving surgery (BCS) became more common while mastec

107 may decrease the reoperation rate in breast-conserving surgery (BCS) compared with rates after surge

108 ists in the use of radiotherapy after breast-conserving surgery (BCS) for ductal carcinoma in situ (D

109 psilateral breast events (IBEs) after breast-conserving surgery (BCS) for ductal carcinoma in situ (D

110 ase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (ER)-posi

111 d for the treatment of DCIS; however, breast-conserving surgery (BCS) has been adopted as the treatme

112 my was performed in 1464 patients and breast-conserving surgery (BCS) in 1395.

113 These 25,000 women included 7300 with breast-conserving surgery (BCS) in trials of radiotherapy (gene

114 Breast-conserving surgery (BCS) is a commonly utilized treatmen

115 Breast conserving surgery (BCS) is a recommended treatment for

116 Radiotherapy (RT) after breast-conserving surgery (BCS) is a standard treatment option

117 PURPOSE Breast-conserving surgery (BCS) is an effective treatment for d

118 Breast-conserving surgery (BCS) is commonly used for the treatm

119 tion of breast cosmesis with a single breast conserving surgery (BCS) is essential for surgeons.

120 Although breast-conserving surgery (BCS) is often assumed to result in m

121 breast tumor recurrence (IBTR) after breast-conserving surgery (BCS) is relatively high.

122 ase for women with DCIS who underwent breast-conserving surgery (BCS) or mastectomy.

123 ification of the tumor margins during breast-conserving surgery (BCS) remains a challenge given the l

124 cted rates of radiation therapy after breast-conserving surgery (BCS) suggest undertreatment.

125 ume surgeons were more likely to have breast-conserving surgery (BCS) than those managed by low-volum

126 with adjuvant radiotherapy (RT) after breast-conserving surgery (BCS) to prevent locoregional recurre

127 rm of breast cancer, are treated with breast-conserving surgery (BCS) when feasible.

128 rt studies show better survival after breast-conserving surgery (BCS) with postoperative radiotherapy

129 Guidelines recommend breast-conserving surgery (BCS) with radiation or mastectomy fo

130 CI, 1.00 to 1.85), and have received breast-conserving surgery (BCS) without radiotherapy (v mastect

131 st for early stage breast cancer: (1) breast conserving surgery (BCS), (2) mastectomy with reconstruc

132 Strategies were breast-conserving surgery (BCS), BCS with 50-Gy radiation (RT)

133 ing NAC, adjuvant chemotherapy (aCT), breast conserving surgery (BCS), bilateral mastectomy (BLM), an

134 he risk of local recurrence following breast-conserving surgery (BCS), even in "low-risk" populations

135 ring partial-breast irradiation after breast-conserving surgery (BCS).

136 have a choice between mastectomy and breast conserving surgery (BCS).

137 o not receive radiation therapy after breast-conserving surgery (BCS).

138 with adjuvant radiotherapy (RT) after breast-conserving surgery (BCS).

139 ne risk score test result and who had breast-conserving surgery (BCS).

140 ection margin is a major challenge in breast conserving surgery (BCS).

141 wire-guided localization (WGL) after breast conserving surgery (BCS).

142 teral mastectomy (UM), and (3) CPM vs breast-conserving surgery (BCS).

143 ry treatment option for most women is breast-conserving surgery (BCS).

144 uate residual tumor immediately after breast-conserving surgery (BCS).

145 lly eligible for either mastectomy or breast-conserving surgery (BCS; n = 125).

146 racteristics, treatments (mastectomy, breast-conserving surgery [BCS] with radiation therapy or alone

147 Breast-conserving surgery combined with axillary lymph node dis

148 Breast-conserving surgery combined with radiation therapy is no

149 he benefit of radiotherapy (RT) after breast-conserving surgery compared with observation.

150 tients with early breast cancer after breast-conserving surgery compared with whole-breast irradiatio

151 gnosed breast cancer who were offered breast-conserving surgery consented from September 2006 to Nove

152 To ensure successful breast conserving surgeries, efficient tumour margin resection

153 risks of invasive breast cancer than breast conserving surgery, even when accompanied by radiotherap

154 Although breast-conserving therapy (breast-conserving surgery followed by radiotherapy) has been as

155 a cohort of young women who underwent breast-conserving surgery followed by radiotherapy.

156 are comparable to outcomes seen after breast-conserving surgery followed by standard whole-breast irr

157 a late relapse a decade or more after breast-conserving surgery for early breast cancer might gain li

158 d or close pathological margins after breast conserving surgery for early stage, invasive breast canc

159 Radiotherapy (RT) after breast-conserving surgery for early-stage disease has become an

160 regarding the optimal margin width in breast-conserving surgery for invasive breast cancer.

161 ients > 40 years of age who underwent breast-conserving surgery for node-negative breast cancer or du

162 Whole-breast irradiation after breast-conserving surgery for patients with early-stage breast

163 random sample of women who underwent breast-conserving surgery for primary DCIS between 2008 and 201

164 lled trial that recruited women after breast-conserving surgery for pT1-3pN0-3aM0 invasive carcinoma

165 least 55 years of age, had undergone breast-conserving surgery for T1N0 (tumor size <2 cm and node n

166 d 50 years or older who had undergone breast-conserving surgery for unifocal invasive ductal adenocar

167 udies reported on patients undergoing breast conserving surgery (for stages I-III breast cancer), all

168 women from receiving the benefits of breast-conserving surgery, forcing them to choose a mastectomy

169 database of DCIS patients undergoing breast-conserving surgery from 1978 to 2010.

170 -one patients with DCIS who underwent breast-conserving surgery from 1996 to 2010 were identified fro

171 were grossly examined at the time of breast conserving surgery from January 2014 to July 2020.

172 those who had mastectomy rather than breast conserving surgery had a lower 25 year cumulative rate o

173 At a time when breast-conserving surgery has become more widely used, this sha

174 500 patients treated with APBI after breast-conserving surgery have been published.

175 Although mastectomy and breast conserving surgery have low risk for complications, few

176 The rate of breast-conserving surgery in both states and the correlates of

177 The rate of breast-conserving surgery in both states was much higher than p

178 atment of breast cancer on the use of breast-conserving surgery in clinical practice.

179 Although the rate of breast-conserving surgery in each state was higher than expecte

180 r the procedure, nearly 75% underwent breast-conserving surgery in Massachusetts and nearly half did

181 Optimal therapy following breast-conserving surgery in older adults with low-risk, early-

182 on the omission of radiotherapy after breast-conserving surgery in older women with hormone receptor-

183 This method allows axilla-conserving surgery in patients responding well to NST.

184 ing multicatheter brachytherapy after breast-conserving surgery in patients with early breast cancer

185 ing multicatheter brachytherapy after breast-conserving surgery in patients with early breast cancer

186 In all patients, breast-conserving surgery included complete gross excision of t

187 Hypofractionated WBI after breast conserving surgery increased among women with early-stag

188 tion of all women who were treated by breast-conserving surgery increased, and because this approach

189 Identifying tumour margins during breast-conserving surgeries is a persistent challenge.

190 Breast-conserving surgery is a more complex treatment than mast

191 Although breast-conserving surgery is a standard approach for patients w

192 east cancer, standard treatment after breast-conserving surgery is adjuvant whole-breast radiotherapy

193 Locoregional failure after breast-conserving surgery is associated with increased risk of

194 The surgical margin status after breast-conserving surgery is considered the strongest predictor

195 when invasive local recurrence after breast-conserving surgery is detected.

196 However, its use during tissue-conserving surgery is limited by time-consuming tissue p

197 er, or ductal carcinoma in situ (when breast-conserving surgery is planned) or are pregnant should no

198 ammatory breast cancer, or DCIS (when breast-conserving surgery is planned) or are pregnant should no

199 ing fact about local recurrence after breast-conserving surgery is that most occurs in the area of br

200 Breast conserving surgery is the preferred treatment for women

201 Tissue-conserving surgery is used increasingly in cancer treatm

202 fter 10 years, but the risk following breast-conserving surgery (lumpectomy) has yet to be determined

203 underwent mastectomy (N = 10,471) and breast conserving surgery (N = 16,517).

204 For women who had breast-conserving surgery (n = 49 166), the authors examined re

205 Fifty-nine percent of women underwent breast-conserving surgery, of whom 81% received radiation thera

206 n undergoing an inappropriate form of breast-conserving surgery (omission of radiotherapy, axillary n

207 First, the effect of oncoplastic breast-conserving surgery on quality of life and the optimal ty

208 ast cancer compared to treatment with breast conserving surgery only (0.86, 0.62 to 1.21).

209 ving surgery plus postoperative RT or breast-conserving surgery only and followed for a median of 15.

210 e 0-II breast cancer and treated with breast-conserving surgery or mastectomy and reconstruction betw

211 through 79 years of age who underwent breast-conserving surgery or mastectomy for local or regional b

212 on aid were 25% more likely to choose breast-conserving surgery over mastectomy (risk ratio, 1.25; 95

213 no more likely than others to undergo breast-conserving surgery (P >.2), but these women were more sa

214 DeltaBF cutoff = -30%; P = 0.03), non-breast-conserving surgery (P = 0.04), and the absence of a path

215 ge I and II were randomly assigned to breast-conserving surgery plus postoperative RT or breast-conse

216 wer mortality than that achieved with breast-conserving surgery plus radiation.

217 1) and, for angiosarcomas, the RR for breast-conserving surgery plus radiotherapy versus mastectomy p

218 ernia, and 0.8% and 0.8% after 42,489 breast-conserving surgery procedures.

219 surgical therapy, radiotherapy after breast-conserving surgery, radiation therapy after mastectomy,

220 women with breast cancer who undergo breast-conserving surgery receive whole-breast irradiation.

221 randomized trials, radiotherapy after breast-conserving surgery reduced mortality from both breast ca

222 ster intraoperative histopathology in breast-conserving surgery, reducing the need for a second opera

223 ive breast cancer to +/- RT following breast-conserving surgery: SweBCG91-RT (stage I-II, no adjuvant

224 ng years due to the increasing use of breast-conserving surgery techniques.

225 Medicare coverage had lower rates of breast-conserving surgery than other women (43.2% vs. 49.2%; ad

226 ely to undergo standard therapy after breast-conserving surgery than other women.

227 urgically treated patients (including breast-conserving surgery), the CPM rate increased by 148% from

228 t DCIS (excluding patients undergoing breast-conserving surgery), the CPM rate increased by 188% from

229 </= 3 cm were randomly assigned after breast-conserving surgery to 3D-CRT APBI (38.5 Gy in 10 fractio

230 our to avoid mastectomy, and to allow breast-conserving surgery to be done.

231 vant radiotherapy is prescribed after breast-conserving surgery to reduce the risk of local recurrenc

232 al trends between patients undergoing breast-conserving surgery, unilateral mastectomy, and CPM.

233 radiation); axillary dissection; and breast-conserving surgery versus mastectomy among women undergo

234 Receipt of breast-conserving surgery versus mastectomy.

235 early breast cancer choosing between breast-conserving surgery vs mastectomy.

236 erall rate of radiation therapy after breast-conserving surgery was 80% in the quality improvement pr

237 bservational data, radiotherapy after breast-conserving surgery was associated with much larger morta

238 Breast-conserving surgery was more frequently performed at teac

239 RT was required if breast-conserving surgery was performed but was elective after

240 of patients undergoing mastectomy and breast conserving surgery was performed from the National Surgi

241 Breast-conserving surgery was possible in 66.6% of the patients

242 Breast-conserving surgery was recommended by surgeons and attem

243 The rate of breast-conserving surgery was up to 8.7 percent higher than exp

244 The rates of breast-conserving surgery were 66.7%, 57.9%, and 68.9% in arms

245 ductal carcinoma in situ treated with breast-conserving surgery were centrally randomised to either w

246 ductal carcinoma in situ treated with breast-conserving surgery were centrally randomly assigned (1:1

247 ve ductal breast carcinoma undergoing breast-conserving surgery were enrolled from 28 centres in nine

248 primary breast cancer ineligible for breast-conserving surgery were randomly assigned to 4 months of

249 Rates of breast-conserving surgery were significantly higher in patients

250 Rates of breast-conserving surgery were similar between the two groups (

251 irectly in the surgical cavity during breast-conserving surgery, which could potentially contribute t

252 s operable and increases the rates of breast-conserving surgery, while achieving similar long-term cl

253 oximately 3% of patients treated with breast-conserving surgery will have an in-breast local recurren

254 In breast-conserving surgery, wire or seed localization and ultras

255 1102 clinical trial demonstrates that breast-conserving surgery with adjuvant radiation that includes

256 published world medical literature on breast-conserving surgery with and without postoperative irradi

257 proven, non-low-risk DCIS treated by breast-conserving surgery with at least 1 mm of clear radial re

258 tomy with axillary node dissection or breast-conserving surgery with axillary node dissection and rad

259 n the largest dimension) treated with breast-conserving surgery with clear excision margins and adjuv

260 ges I or II breast cancer, excised by breast conserving surgery with negative margins, were eligible

261 R2 negative carcinoma <= 20 mm) after breast-conserving surgery with negative margins.

262 iotherapy 19.8% (16.2% to 23.4%), and breast conserving surgery with no radiotherapy recorded 20.6% (

263 th radiotherapy 8.6% (5.9% to 15.5%), breast conserving surgery with no radiotherapy recorded 7.8% (6

264 erving surgery with radiotherapy, and breast conserving surgery with no radiotherapy recorded.

265 ilateral invasive breast cancer after breast-conserving surgery with or without adjuvant radiotherapy

266 om patients who had been treated with breast-conserving surgery with or without postoperative radiati

267 In women who underwent breast conserving surgery with or without radiotherapy, only ad

268 low-up of randomised trials comparing breast-conserving surgery with or without radiotherapy.

269 Compared with breast-conserving surgery with radiation (10-year mortality, 16

270 between 1998 and 2007, who underwent breast-conserving surgery with radiation (breast-conserving the

271 CI, 1.02 to 1.73) more likely to get breast-conserving surgery with radiation than other types of tr

272 tions for early breast cancer include breast-conserving surgery with radiation therapy (RT) or mastec

273 d on National Guidelines as receiving breast-conserving surgery with radiation therapy and axillary n

274 of definitive surgery (mastectomy or breast-conserving surgery with radiation v breast-conserving su

275 egional treatment comparing 3 groups: breast-conserving surgery with radiotherapy (BCS+RT), mastectom

276 5% conference interval 7.0% to 9.4%), breast conserving surgery with radiotherapy 19.8% (16.2% to 23.

277 cer (mastectomy 6.5% (4.9% to 10.9%), breast conserving surgery with radiotherapy 8.6% (5.9% to 15.5%

278 nd radiotherapy with RNI; 0.55% after breast-conserving surgery with radiotherapy without RNI; 0.11%

279 eath appeared similar for mastectomy, breast conserving surgery with radiotherapy, and breast conserv

280 551 (85.2%) confirmed treatment with breast-conserving surgery with RT (n = 315) or mastectomy and r

281 wed no significant difference between breast-conserving surgery with RT (referent) and mastectomy and

282 The findings support equivalence of breast-conserving surgery with RT and mastectomy and reconstruc

283 Breast-conserving surgery with RT or mastectomy and reconstruct

284 However, breast-conserving surgery with RT was associated with clinicall

285 ed that their surgeon did not discuss breast-conserving surgery with them.

286 RO) guideline on surgical margins for breast-conserving surgery with whole-breast irradiation in stag

287 atic SLNs who are planning to undergo breast-conserving surgery with whole-breast radiotherapy should

288 o metastatic SLNs planning to undergo breast-conserving surgery with whole-breast radiotherapy should

289 carcinoma in situ (DCIS) treated with breast-conserving surgery without adjuvant radiation therapy (R

290 s lower (3.7% vs 5.0%; P < .001), and breast-conserving surgery without other treatment was more freq

291 t-conserving surgery with radiation v breast-conserving surgery without radiation); axillary dissecti

292 Among women who had breast-conserving surgery, women with SSDI and Medicare coverag